Year: 2024
Type: article
Abstract: Antimicrobial resistance (AMR) is a serious threat to global public health, with approximately 5 million deaths associated with bacterial AMR in 2019. Tackling AMR requires a multifaceted and cohesive approach that ranges from increased understanding of mechanisms and drivers at the individual and population levels, AMR surveillance, antimicrobial stewardship, improved infection prevention and control measures, and strengthened global policies and funding to development of novel antimicrobial therapeutic strategies. In this rapidly advancing field, this Review provides a concise update on AMR, encompassing epidemiology, evolution, underlying mechanisms (primarily those related to last-line or newer generation of antibiotics), infection prevention and control measures, access to antibiotics, antimicrobial stewardship, AMR surveillance, and emerging non-antibiotic therapeutic approaches. The Review also discusses the potential roles of artificial intelligence in addressing AMR, including antimicrobial susceptibility testing, AMR surveillance, antimicrobial stewardship, diagnosis, and antimicrobial drug discovery and development. This Review highlights the urgent need for addressing the global effects of AMR and for rapid advancement of relevant technology in this dynamic field.
Source: The Lancet Microbe
Institutions: Western Eye Hospital, Charing Cross Hospital, Nanyang Technological University, Singapore Eye Research Institute, Duke-NUS Medical School, National University of Singapore, Singapore National Eye Center, Birmingham and Midland Eye Centre, University of Birmingham, HUN-REN Szegedi Biológiai Kutatóközpont, Institute of Biochemistry, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, University of Pennsylvania, University of British Columbia, University of Nottingham, Sandwell & West Birmingham Hospitals NHS Trust
Language: English
Subfield: Applied Microbiology and Biotechnology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,300
Funders: Hungarian Research Network, Birmingham Health Partners, Brain and Behavior Research Foundation, Impact Fund, Procter and Gamble, University of Pennsylvania, United Therapeutics Corporation, National Institute for Health and Care Research, European Commission, Killam Trusts, University of British Columbia, National Institutes of Health, Defense Threat Reduction Agency, Perelman School of Medicine, University of Pennsylvania, Horizon 2020 Framework Programme, Canadian Institutes of Health Research, Medical Research Council, Invention for Innovation, Birmingham Biomedical Research Centre, National Institute of General Medical Sciences, HORIZON EUROPE European Research Council
Awards: G1143353636, G1156184107, G1590412184, G1738785605, G1973820006, Impact of Oral Disulfiram on Aldehyde Dehydrogenase (ALDH) Mediated Ocular Fibrosis in Mucous Membrane Pemphigoid (OcMMP), G2041698327, G2233587286, G2274584244, G2350218693, G3363483690, G434337789, Human Hybrid Antimicrobial Peptides for Corneal Infection: From Molecular Dynamic Simulation to In Vivo Animal Studies, G4950536974, Development of a synthetic flowable dressing that prevents corneal scarring, Fluid-Gels as Resorbable Protective Dressings for Ocular Surface Disease, G676283229, Establishing the Hungarian Center of Excellence for Molecular Medicine in partnership with EMBL, MRC IAA 2021 University of Birmingham, G9000100084
OpenAlex ID: W4402655854